Wuerzburg, Germany

Heidrun Moll

This inventor holds 1 USPTO granted patent and 2 EPO patents. Top assignee: Julius-Maximilians-Universitaet Wuerzburg. Active years: 2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Heidrun Moll. Retrieved from https://idiyas.com/inventor/heidrun-moll

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile



Average Co-Inventor Count = 12.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Heidrun Moll: Innovator in Anti-Infective Research

Introduction

Heidrun Moll is a notable inventor based in Würzburg, Germany. She has made significant contributions to the field of anti-infective research, particularly through her innovative work on aryl isoquinoline-derivatives.

Latest Patents

Heidrun Moll holds 1 patent that focuses on the anti-infective and biofilm-inhibiting activities of aryl isoquinoline-derivatives. The patent describes the general formulae 1 to 3, showcasing her commitment to advancing medical science.

Career Highlights

Throughout her career, Heidrun Moll has been associated with prestigious institutions, including Julius-Maximilians-Universität Würzburg. Her work at this university has been instrumental in her research endeavors.

Collaborations

Heidrun has collaborated with esteemed colleagues such as Gerhard Bringmann and Tanja Gulder. These partnerships have enriched her research and contributed to her innovative projects.

Conclusion

Heidrun Moll's contributions to anti-infective research highlight her role as a pioneering inventor in her field. Her work continues to inspire advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…